Healthcare · Biotechnology

Moderna, Inc.

EXCHANGE: MRNA ·USD ·United States
CEO & Director Mr. Stéphane Bancel M.B.A.
48 Months —

Price Chart

Last 12 months · daily close · updated after market close
12-Month Chart
— —
— —

Key Metrics

Updated May 13, 2026
52 Week Range
22.28 – 59.55
Day Range
49.99 – 53.06
EPS (FWD)
-4.16
PE (TTM)
—
PE (FWD)
-12.80
Div Rate (FWD)
—
Yield (FWD)
—
Short Interest
17.98%
Market Cap
$21.14 B
Prev. Close
53.27

Analyst Consensus

Consensus Rating
HOLD
Analysts
19
covering this stock
Mean Target
$43.37
-14.0% vs current
Current Price
$50.42
-5.35% today
12-Month Price Target Range
MEAN TARGET
$43.37
NOW $50.42
LOW TARGET
$21.00
HIGH TARGET
$69.00
Range based on 19 Wall Street analysts covering MRNA.
Recent Analyst Actions — 7 unique firms, latest first
  • May 4, 2026 Maintain UBS Neutral (+$36 → $45)
  • May 4, 2026 Maintain Goldman Sachs Neutral (+$43 → $49)
  • May 4, 2026 Maintain Evercore ISI Group In-Line (+$35 → $50)
  • May 4, 2026 Maintain RBC Capital Sector Perform (+$35 → $38)
  • Apr 2, 2026 Maintain Barclays Equal-Weight (+$25 → $48)
  • Feb 23, 2026 Maintain Piper Sandler Overweight (+$63 → $69)
  • Dec 12, 2025 Maintain Morgan Stanley Equal-Weight ($30 → $28)
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, …
Website
www.modernatx.com ↗
ISIN
US60770K1079
Quarter Revenue YoY Net Income EPS (Diluted) YoY Gross Margin Op. Margin
Q1 2026 Mar 2026 $389.0M +263.6% $-1.34B $-3.40 -34.9% -145.5% -356.8%
Q4 2025 Dec 2025 $676.0M — $-826.0M $-2.11 — 33.1% -126.8%
Q3 2025 Sep 2025 $1.00B — $-200.0M $-0.51 — 79.3% -26.0%
Q2 2025 Jun 2025 $137.0M — $-825.0M $-2.13 — 13.1% -662.0%
Q1 2025 Mar 2025 $107.0M — $-971.0M $-2.52 — 15.9% -981.3%

Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.

MetricCurrentForward
EPS—$-4.16
Revenue—$2.22 B
P/E—-12.80
Dividend——
Profit Margin-1.44%—
PEG Ratio——
Beta (5Y)1.06—
Rate (FWD)
—
Yield (FWD)
—
Payout Ratio
0.00%
Ex-Div Date
—
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Latest MRNA Coverage